Abstract
Purpose :
To evaluate the outcome of an exit strategy intravitreal treatment in Treat and Extend regimen in exudative macular degeneration
Methods :
This was a french monocentric retrospective study that included 30 eyes with neovascular AMD. All patients received intravitreal anti-vascular endothelial growth factor injections according to a treat and extend regimen.
Exit criteria were defined as follows: when the interval is extended to 12 weeks with no signs of activity disease, patients received 4 consecutive injections before stop treatment. All patients had minimal duration of treatment of two years.
Best corrected visual acuity before exit treatment, Final best corrected visual acuity, duration of therapy, incidence of recurrence and characteristics of recurrence were collected.
Results :
Thirty eyes were included in this study.
The mean treatment duration was 66 ± 21 months (5.5 ± 1.75 years). The mean duration of follow-up after exit treatment was 25 ± 12 months.
Twenty-three percent patients had recurrent disease after exit treatment. In these eyes, the mean of recurrent disease was 15 ± 11 months and 71 % of this group "recurrent disease" had recurrence the first year after exit treatment.
The main characteristics of recurrence were haemorrhages in 57%, subretinal fluid in 14% and intraretinal fluid in 28%
Conclusions :
The high proportion of patients with no recurrence after exit treatment involve that we have to try to screen these "happy few patients of exit treatment".
This is a 2020 ARVO Annual Meeting abstract.